Neuronetics Unveils New Depression Data at Clinical TMS Society’s Virtual Events
22 September 2020 - 10:00PM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, will present clinical data and host
virtual educational sessions as part of the Clinical TMS Society’s
virtual programming.
The Clinical TMS Society, a professional association that aims
to optimize awareness and accessibility of transcranial magnetic
stimulation (TMS) therapy, is hosting virtual events this year in
place of its traditional Annual Meeting, giving attendees a chance
to experience educational sessions remotely. As a sponsor,
Neuronetics will present a product theater webinar and two virtual
poster presentations detailing the company’s latest research with
NeuroStar Advanced Therapy in bipolar and unipolar depression.
On Tuesday, September 29 at 5:30 p.m. PDT (8:30 p.m. EDT),
Neuronetics will host a product theater webinar that will address
these two topics:
- Treatment of Bipolar Depression: A Pilot Study—Clinical
experience has suggested that NeuroStar Advanced Therapy might be
effective for bipolar depression. This presentation will review the
existing literature on the efficacy of TMS for bipolar depression
and present the findings from a two-center open-label prospective
trial of NeuroStar Advanced Therapy in bipolar depression including
type I and type II patients.
“With so few treatments available for the management of bipolar
depression, making TMS a non-drug treatment option could be
groundbreaking,” said Dr. Scott Aaronson, Director of Clinical
Research at Sheppard Pratt Health System and lead investigator of
the study. “Results from this open label pilot study are quite
promising and should lead to further efforts to make this treatment
available to help as many patients as possible.”
- Clinical Outcomes of NeuroStar Advanced Therapy Treatment: The
Largest Patient Registry for Depression Treatment with Transcranial
Magnetic Stimulation—With more than 9,000 patients across more than
100 private practice locations in the U.S., Neuronetics’ Outcomes
Registry is the largest registry documenting outcomes for any
treatment of Major Depressive Disorder (MDD). This presentation
will report new findings from the registry about the efficacy of
NeuroStar Advanced Therapy in adult patients treated for an episode
of MDD in community settings.
“Findings from Neuronetics’ Outcomes Registry document
real-world outcomes, and further demonstrate that NeuroStar
Advanced Therapy delivered in the community setting is an effective
treatment for depression,” said Dr. Harold A. Sackeim, Professor of
Clinical Psychology in Psychiatry and Radiology at the College of
Physicians and Surgeons, Columbia University and lead author of the
study. “Results from this large registry will help improve
depression treatment protocols and treatment plans for individual
patients.”
In addition, the following NeuroStar poster presentations will
be on display throughout the duration of the virtual poster session
from now through Saturday, October 31:
- Poster #63: Comparison of Naturalistic Treatment Outcomes with
the Standard 38-Minute Protocol vs. Shortened (“DASH”) Protocol: A
NeuroStar Registry Database Study—Based on a subset analysis of
over 7,700 patients from the NeuroStar Outcomes Registry, data
demonstrates that efficacy is statistically similar between
patients who received the Standard treatment protocol at 38 minutes
per session compared to the DASH protocol at 19 minutes per
session.
Dr. Scott West, Medical Director at Nashville NeuroCare Therapy
and lead author of the DASH protocol poster commented, “The
response rates we’ve seen are comparable between NeuroStar’s
standard and DASH treatment protocols, which provide support for a
shorter session as an effective treatment solution. Research like
this underscores Neuronetics’ commitment to providing safe and
effective depression treatments for clinicians and patients.”
- Poster #10: Post Marketing Rate of Seizures During Transcranial
Magnetic Stimulation (TMS) Treatment with NeuroStar Advanced
Therapy Is Low—In analyzing the seizure rate from post marketing
surveillance and from literature related to Neuronetics-sponsored
clinical trials, it was found that the rate of seizures reported
during TMS treatments with the NeuroStar Advanced Therapy device
was even lower than previously estimated.
The Clinical TMS Society encourages attendees to register for
the virtual events as early as possible. Those interested in
attending the webinar can register online here until Monday,
September 28. Those interested in viewing poster presentations can
register online here.
As a company focused on improving quality of life for patients
facing mental health challenges, Neuronetics continues to support
investigator-initiated clinical trials in different areas of
research and conditions to advance neurohealth. NeuroStar is FDA
cleared as a safe and effective option for adult patients with
Major Depressive Disorder and recently received Breakthrough Device
Designation to conduct research with NeuroStar for bipolar
depression. For more information, visit www.neurostar.com.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Our commercial
product, the NeuroStar® Advanced Therapy System, is a non-invasive
and non-systemic office-based treatment that uses transcranial
magnetic stimulation, or TMS, to create a pulsed, MRI-strength
magnetic field that induces electrical currents designed to
stimulate specific areas of the brain associated with mood. The
system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national health
insurance. Additional information can be found at
www.neuronetics.com.
Media Contact: Meagan DominickVault
Communications610-455-2779mdominick@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2024 to May 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From May 2023 to May 2024